SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1523)4/4/1998 11:47:00 AM
From: Bob L  Read Replies (1) of 1762
 
Since you are reduced to taking sample sizes of one, here is another. And this one is second-hand, too.

I'm told that at least one patient in the Bexxar study, who did not have a significant response, went on to try Rituxan and had a good response to that. This person is swimming against the current of conventional wisdom, under which we all assume that the hot monoclonals will be better than the cold ones. It just shows that patients are individuals and that NHL varies greatly among individuals. It also shows, in my opinion, that there will be plenty of room for competition among the new treatments as doctors and patients work out which works best for whom.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News